Psychedelic Stocks,Shroom News Silo Wellness Contemplating Uplisting On the Nasdaq Market By Dennis Mutua April 23, 2021 Health and wellness company focusing on psychedelics therapies Silo Wellness Inc. (OTCQB: SILO) is gearing up to secure an uplist to the Nasdaq capital market. The biotechnology company made the announcement after the company’s ...
Featured,Spotlight Stock,Trends & Articles Revive Therapeutics Completes Research on Oral Thin Film Psilocybin By Dennis Mutua April 23, 2021 Life sciences company specializing on research and development of therapies for infectious diseases and rare disorders Revive Therapeutics Ltd (CNSX: RVV) announced successful completion of its research on oral thin film (OTF) del...
Psychedelic Stocks,Shroom News ATAI Life Sciences Preparing for a $100 Million IPO By Dennis Mutua April 22, 2021 Clinical stage Bioscience Company focusing on treatment of mental illness ATAI Life Sciences says that it’s anticipating to raise $100 million from its upcoming initial public offering. The company made its IPO regulatory filing...
Featured,Spotlight Stock,Trends & Articles Proprietary Mushrooms Shows Efficacy in Killing Breast Cancer Cells Says Aion Therapeutics By Dennis Mutua April 22, 2021 Life Sciences Company concentrating on research and production of medical cannabis and psychedelics therapies Aion Therapeutics Inc. (CNSX: AION) announced its proprietary and patented combinatorial mushroom preparations AION F7 a...
Psychedelic Stocks,Shroom News Prof Benjamin Kelmendi Appointed to the Scientific Advisory Board of Lobe Sciences By Dennis Mutua April 21, 2021 Growth oriented life sciences company specializing on psychedelics Lobe Sciences Ltd (CSE: LOBE) (OTC: GTSIF) has appointed Professor Benjamin Kelmendi to its scientific advisory board. Professor Kelmendi serves as an assistant Pr...
Featured,Spotlight Stock,Trends & Articles PharmaTher Submits Phase 2 Clinical Trials Application for Using Ketamine to Treat Parkison’s Disease By Dennis Mutua April 21, 2021 Life Sciences company focusing on research and development of psychedelic pharmaceuticals PharmaTher Holding Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having submitted an application to commence its phase 2 clinical trials to asse...
Featured,Shroom News,Spotlight Stock Halucenex Signs Agreement With Sixth Wave to Progress Research of Hallucinogenic Mushrooms By Dennis Mutua April 20, 2021 Life sciences development company focusing on novel psychedelics compounds to treat mental illnesses Halucenex Life Sciences has signed a non-binding letter of agreement (LOI) of agreement with Sixth Wave, a leading nanotechnology...
Featured,Trends & Articles U.S Psychedelics Drug Market Expected to Reach $6.9 Billion by 2027 By Dennis Mutua April 20, 2021 A business intelligent report released on 19 April by Department for BioMedical Research (DBMR) suggests that the psychedelics drug market in the United States will be worth over $6.85 billion by the year 2027. This projection ...